Doylestown, PA, United States of America

Stuart Emanuel

This inventor holds 29 USPTO granted patents and 5 published patent applications and 5 EPO patents, primarily in Cancer Therapeutics. Top assignees: Janssen Pharmaceutica Nv, Bristol-Myers Squibb Compnay, Janssen Biotech, Inc.. Active years: 2004-2023.

USPTO Granted Patents = 29 (Patent Applications = 5)

% Patents Active = 69.0

EPO Patents = 5 (Patent Applications = 5)

Average Co-Inventor Count = 6.3

ph-index = 9

Forward Citations = 335(Granted Patents)

Location History:

Doylestown, PA (US) (2004 - 2022)
Spring House, PA (US) (2023)

Company Filing History:

12 out of 2,099

Janssen Pharmaceutica Nv

patents

9 out of 3,736

Bristol-Myers Squibb Compnay

patents

4 out of 433

Janssen Biotech, Inc.

patents

4. 4 out of 363

Ortho-Mcneil Pharmaceutical Corp.

patents

Years Active: 2004-2023

Loading Chart...

Areas of Expertise:

Cyclic Dinucleotides

Bispecific Binding Molecules

EGFR

Targeted Therapeutics

Kinase Inhibitors

Polynucleotides

Pyrimidine Compounds

Cell Proliferative Disorders

VEGF Modulators

Amino Substituted Compounds

Triazole Derivatives

Tyrosine Kinases

29 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11597746 - Cyclic dinucleotides as sting agonists (2023-03-07),

2. 11492367 - Cyclic dinucleotides as sting agonists (2022-11-08),

3. 11472830 - Cyclic dinucleotides as sting agonists (2022-10-18),

4. 11021511 - Cyclic dinucleotides as sting agonists (2021-06-01),

5. 10954286 - Bispecific EGFR/IGFIR binding molecules (2021-03-23),

6. 10781247 - Targeted therapeutics based on engineered proteins that bind EGFR (2020-09-22),

7. 10183987 - Polynucleotides encoding bispecific EGFR/IGF-IR binding molecules (2019-01-22),

8. 9920108 - Targeted therapeutics based on engineered proteins that bind EGFR (2018-03-20),

9. 9771411 - Method of treating cancer by administering EGFR and EGFR/IGFIR binding molecules (2017-09-26),

10. 9234028 - Targeted therapeutics based on engineered proteins that bind EGFR (2016-01-12),

11. 9017655 - Bispecific EGFR/IGFIR binding molecules (2015-04-28),

12. 8524244 - Targeted therapeutics based on engineered proteins that bind EGFR (2013-09-03),

13. 8367825 - Substituted pyrimidinyl oxime kinase inhibitors (2013-02-05),

14. 8343501 - Bispecific EGFR/IGFIR binding molecules (2013-01-01),

15. 8314234 - Bicyclic pyrimidine kinase inhibitors (2012-11-20),

Title: Innovations of Stuart Emanuel: A Pioneer in STING Modulation

Introduction

Stuart Emanuel, based in Doylestown, PA, is an accomplished inventor with a remarkable portfolio of 29 patents. His innovative contributions primarily focus on the modulation of STING (Stimulator of Interferon Genes) pathways, which have significant implications for treating various diseases and disorders.

Latest Patents

Among his most recent patents, Stuart has developed cyclic dinucleotides as STING agonists. These compounds, compositions, and methods are aimed at treating diseases, syndromes, or disorders impacted by STING modulation. The inventive compounds are represented by specific formulas that detail the arrangement of various chemical components.

Career Highlights

Stuart has made significant strides in the pharmaceutical industry, working with leading companies such as Janssen Pharmaceutica and Bristol-Myers Squibb Company. His expertise in drug discovery and development has allowed him to contribute substantially to advancements in therapeutic options for numerous health challenges.

Collaborations

Throughout his career, Stuart has collaborated with prominent professionals in the field, including coworkers Peter J. Connolly and Steven A. Middleton. These collaborations are indicative of a strong network that supports innovation and progress in medical research.

Conclusion

Stuart Emanuel stands out as an influential inventor in the realm of STING modulation. His 29 patents reflect a commitment to innovation and a dedication to addressing pressing medical issues. With ongoing research and collaboration, his work continues to pave the way for potential breakthroughs in therapeutic solutions.